Belumosudil

chronic graft-versus-host disease (chronic GVHD): A condition that can develop after a stem cell or bone marrow transplant, where the donor's immune cells attack the recipient's own body tissues.

kinase inhibitor: A type of drug that blocks specific enzymes called kinases, which relay signals inside cells — often used to interrupt overactive immune or cancer-related signaling.

ROCK1 / ROCK2: Rho-associated coiled-coil containing protein kinases — enzymes that help regulate immune responses and tissue scarring; belumosudil works by blocking these.

systemic therapy: Treatment that travels through the whole body (such as pills or infusions), as opposed to a cream or local treatment applied to one spot.

fibrosis: The buildup of excess scar tissue inside organs or other body tissues, which can impair their function.

STAT3 / STAT5: Proteins inside cells that carry inflammatory signals; belumosudil helps regulate these to reduce immune overreaction.

Th17 / Treg cells: Types of immune cells — Th17 cells drive inflammation, while Treg cells help keep it in check; belumosudil helps restore a healthier balance between them.

embryo-fetal toxicity: The potential for a drug to cause harm to a developing embryo or fetus during pregnancy, including birth defects or pregnancy loss.

proton pump inhibitor (PPI): A common class of acid-reducing medications (such as omeprazole or pantoprazole) used to treat heartburn, ulcers, and acid reflux.

CYP3A: A key enzyme in the liver responsible for breaking down many medications; drugs that speed up or slow down CYP3A can change how much of another drug stays in your blood.

CYP3A inducer: A drug or substance that speeds up the CYP3A enzyme, causing certain medications to be broken down faster and potentially become less effective.

BCRP substrate: A drug that is transported out of cells by a protein called BCRP (breast cancer resistance protein); belumosudil blocks this protein and can raise levels of these drugs.

OATP1B1 substrate: A drug transported into liver cells by the OATP1B1 protein; belumosudil may block this transporter, raising blood levels of those drugs.

P-gp (P-glycoprotein): A protein that pumps certain drugs out of cells; drugs that inhibit P-gp (like belumosudil) can increase the blood levels of drugs that rely on it.

UGT1A1: A liver enzyme involved in breaking down certain drugs; belumosudil can inhibit it, potentially raising levels of drugs processed this way.

ALT / AST: Liver enzymes (alanine aminotransferase and aspartate aminotransferase) measured in blood tests to check for liver damage or inflammation.

bilirubin: A yellow substance produced when red blood cells break down; high bilirubin levels in the blood can indicate liver problems.

hepatic impairment: Reduced liver function, often graded as mild, moderate, or severe, which can affect how drugs are processed.

renal impairment: Reduced kidney function, which can affect how drugs and their byproducts are cleared from the body.

QT interval: A measurement on a heart tracing (ECG) that reflects the timing of the heart's electrical cycle; some drugs can dangerously prolong it, increasing the risk of an abnormal heart rhythm.

half-life: The time it takes for the amount of a drug in the body to fall by half; a longer half-life generally means the drug stays active in the body for a longer time.

bioavailability: The fraction of a drug dose that actually reaches the bloodstream and is available to work in the body.

absorption: The process by which a drug passes from the gut into the bloodstream after you take it by mouth.

contraception: Methods used to prevent pregnancy, such as barrier methods, hormonal pills, or IUDs.

pharmacokinetics: The study of how the body absorbs, distributes, breaks down, and eliminates a drug over time.

organogenesis: The stage of fetal development during which the baby's organs are forming — a particularly sensitive period for potential drug-related harm.

edema: Swelling caused by fluid building up in body tissues, commonly in the legs, feet, or face.

asthenia: A medical term for weakness or lack of energy; often reported by patients as fatigue or feeling run-down.

dyspnea: Shortness of breath or difficulty breathing.

hemorrhage: Bleeding, which can range from minor bruising to more serious internal or external blood loss.

gamma-glutamyl transferase (GGT): A liver enzyme measured in blood tests; elevated levels can indicate liver stress or damage.

lymphocytes: A type of white blood cell that plays a key role in the immune system; low levels can increase the risk of infection.

Child-Pugh score: A scoring system used to assess the severity of liver disease, with classes A (mild), B (moderate), and C (severe).

reproductive potential: The ability to conceive or father a child; used in drug labeling to identify people who need contraception advice.

post-implantation loss: The loss of an embryo after it has implanted in the uterus, which can result in early pregnancy loss.

abdominal pain: Pain, cramping, or discomfort felt anywhere in the belly area.

Adverse Reactions: Unwanted or harmful effects that people experienced while taking a medicine, listed on its official label.

ALT: A liver enzyme (alanine aminotransferase) checked by a blood test; raised levels can signal that the liver is irritated or damaged.

AST: A liver enzyme (aspartate aminotransferase) measured in a blood test; higher levels may point to liver or sometimes muscle injury.

BCRP: A protein pump that moves certain drugs out of cells, affecting how much of the drug is absorbed.

Clinical Studies: The label section summarizing the research trials used to show that a medicine works and is acceptably safe.

CYP1A2: A liver enzyme that breaks down certain medicines and whose activity can be changed by cigarette smoke.

diarrhea: Loose, watery bowel movements that happen more often than normal.

Dosage and Administration: The label section explaining how much of a medicine to use and how to take or give it.

fertility: The natural ability to become pregnant or to father a child.

fetal harm: Injury or damage to a developing baby while it is growing inside the womb.

Indications and Usage: The label section stating which medical conditions the FDA has officially approved the medicine to treat, prevent, or manage.

inhibitor: A substance that blocks an enzyme or transporter, which can raise the levels of drugs it normally handles.

NDC: A unique number that identifies a specific medicine, its maker, strength, and package size.

nursing infant: A baby who is being fed breast milk.

P-gp: A protein pump in cells that pushes certain drugs back out, limiting how much is absorbed or reaches tissues.

respiratory failure: A serious condition in which the lungs cannot get enough oxygen into the blood or remove enough carbon dioxide.

seizure: A sudden burst of abnormal electrical activity in the brain that can cause shaking, staring, confusion, or loss of awareness.

substrate: A drug or other substance that a particular enzyme or transporter acts on.

Warnings and Precautions: The label section describing serious risks to know about and safety steps to follow while using a medicine.